Evommune Inc. (EVMN)
EVMN trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/2044725/000119312526093932/0001193125-26-093932-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | EVMN on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0002044725 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $13.0M |
| Net income | -$68.9M |
| Operating income | -$81.1M |
| Net margin | -529.8% |
| Operating margin | -623.6% |
| Revenue growth | +85.7% |
| Cash | $44.1M |
| Total assets | $224.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 22.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $47.6M cash; operating cash flow -$22.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 41,349,860 (2026-11-10); 31,524,093 a year earlier. | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., New York, New York, United States | PCAOB Form AP 2026-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $45.2M, sold $2.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$30.9M | -$25.9M | $47.6M | No debt tags | $0 | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $0 | -$32.2M | -$20.3M | $60.0M | No debt tags | $10.0M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $0 | -$21.7M | -$27.5M | $48.3M | No debt tags | $10.0M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $0 | -$28.3M | -$16.7M | $44.1M | No debt tags | $13.0M | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | $10.0M | -$12.5M | -$9.6M | $26.8M | No debt tags | $13.0M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $0 | -$13.6M | -$26.2M | $61.8M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $3.0M | -$14.6M | -$23.9M | $5.7M | No debt tags | Needs four quarters | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $0 | -$20.7M | -$18.5M | $16.3M | No debt tags | $7.0M | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-11-12 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-21 |
Source: SEC EDGAR submissions feed, 144 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +14.7% |
| 1 month | +29.8% |
| 3 months | -45.8% |
| Year to date | -55.4% |
| 1 year | -58.1% |
| From 52-week high | -75.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| EBS | Emergent BioSolutions Inc. | $5.81 | +0.35% | $298.7M |
| ALT | Altimmune Inc. | $1.56 | -5.17% | $303.6M |
| FULC | Fulcrum Therapeutics Inc. | $3.71 | -1.59% | $283.4M |
| GALT | Galectin Therapeutics Inc. | $3.02 | -0.98% | $305.2M |
| BNTC | Benitec Biopharma Inc. | $8.54 | -5.53% | $308.5M |
| ENTA | Enanta Pharmaceuticals Inc. | $10.67 | -2.91% | $310.8M |
| LRMR | Larimar Therapeutics Inc. | $3.00 | -0.66% | $311.6M |
| PRLD | Prelude Therapeutics Incorporated | $3.41 | -1.16% | $272.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier